FDA clears second-generation Monarch eTNS System for treating pediatric ADHD
The FDA has cleared NeuroSigma’s second-generation Monarch eTNS System for treating pediatric ADHD. The device is smaller and includes a high-resolution color LCD screen and optimized user interface. It is indicated for patients aged 7 to 12 years who are not currently taking ADHD medications. NeuroSigma plans to scale its commercial operations to help treat…